Summary
Resistance to anthracyclines is the major factor limiting their clinical utility. Laboratory studies using cultured experimental and human tumour cells have indicated that reduced intracellular drug accumulation is one important factor underlying resistance. In some systems this results from enhanced active drug efflux, a process which may be circumvented experimentally, for example by calcium antagonists. A specific glycoprotein which is produced in excess and is inherited has been identified in the cell membrane of certain anthracycline-resistant cells, while gene amplification with the appearance of double-minute chromosomes has been noted in others.
Thus it is possible that anthracycline resistance arises following inherited changes in the cell membrane resulting in failure of drug accumulation. However, other possibilities exist, including differences in drug binding, either to the cell membrane or to nuclei, differences in metabolism to the semiquinone free radical, and differences in drug penetration related to tumour morphology.
For each human tumour type the factor(s) involved may differ, but sufficient clues now exist to suggest that clinical testing of some of the therapeutic possibilities for circumventing anthracycline resistance may soon be appropriate.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Baskin F, Rosenberg RN, Dev V (1981) Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. Proc Natl Acad Sci USA 78: 3654–3658
Beck WT (1983) Vinca-alkaloid-resistant phenotype in cultured human leukaemic lymphoblasts. Cancer Treat Rep 67: 875–882
Beck WT, Cirtain MC (1982) Continued expression of vinca-alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase. Cancer Res 42: 184–189
Beck WT, Mueller TJ, Tanzer LR (1979) Altered surface membrane glycoproteins in vinca-alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39: 2070–2076
Biedler JL, Riehm H, Peterson RHF, Spengler BA (1975) Membrane-mediated drug resistance and phenotypic reversion to normal growth behavior of Chinese hamster cells. J Natl Cancer Inst 55: 671–680
Biedler JL, Chang T, Meyers MB, Peterson RHF, Spengler BA (1983) Drug resistance in Chinese hamster lung and mouse tumor cells. Cancer Treat Rep 67: 859–868
Bonnadonna G, Monfardini S, Delara M (1970) Phase I and preliminary phase II evaluation of adriamycin. Cancer Res 30: 2572–2576
Bozzi A, Marelli I, Mondori B, Strom R, Rotilio G (1981) Differential cytotoxicity of daunomycin in tumor cells is related to glutathione-dependent hydrogen peroxide metabolism. Biochem J 194: 369–374
Carman MD, Shornagel JH, Rivest RS, Srimatkandanda S, Portlock CS, Duffy T, Bertino JR (1984) Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol 2: 16–20
Chitnis MP, Joshi SS, Gude RP, Menon RS (1982) Induced resistance in leukaemia L1210 to adriamycin and its cross resistance to vincristine and bouvardin. Exp Chemother 28: 209–212
Chlebowski RT, Block JB, Cundiff D, Dietrich MF (1982) Doxorubicin cytotoxicity enhanced by local anaesthetics in a human melanoma cell line. Cancer Treat Rep 66: 121–125
Chou T-H, Kessel D (1981) Effects of tumicamycin on anthracycline resistance in P388 murine leukaemia cells. Biochem Pharmacol 30: 3134–3136
Curt GA, Carney DN, Cowan KH (1983) Unstable methotrexate resistance in human small cell carcinoma associated with double-minute chromosomes. N Engl J Med 308: 199–202
Dalmark M, Storm HH (1981) A Fickian diffusion transport process with features of transport catalysis. J Gen Physiol 78: 349–364
Dano K (1971) Development of resistance to daunomycin in Ehrlich ascites tumor. Cancer Chemother Rep 55: 133–141
Dano K (1972) Cross resistance between vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo. Cancer Chemother Rep 56: 701–708
Dano K (1973) Active outward transport of daunomycin in resistance Ehrlich ascites tumor cells. Biochim Biophys Acta 323: 466–483
Debenham PG, Kartner N, Siminovitch L, Riordan JR, Ling V (1982) DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Mol Cell Biol 2: 881–889
Donehower RC, Myers CE, Chabner BA (1979) New developments on the mechanisms of action of neoplastic drugs. Life Sci 25: 1–14
Friche E, Skovsgaard T, Nissen NI, Dimarco A, Dano K (1983) Accumulation of daunorubicin analogues in daunorubicin-resistant cells and their effect on accumulation of 3H-daunorubucin. In: Hansen HH (ed) Anthracyclines and cancer therapy. Excerpta Medica, Amsterdam, pp 49–55
Garman D, Center MS (1982) Alterations in cell surface membranes in Chinese hamster lung cells resistant to adriamycin. Biochem Biophys Res Commun 105: 157–163
Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733
Houghton PJ, Houghton JA (1983) Chemotherapeutic response in xenografts: inter- and intra-tumour heterogeneity. In: Chabner BA (ed) Rational basis for chemotherapy. Liss, New York, pp 61–69
Inaba M, Johnson RK (1978) Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukaemia. Biochem Pharmacol 27: 2123–2130
Inaba M, Kobayasui H, Sakurai Y, Johnson RK (1979) Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukaemia. Cancer Res 39: 2200–2203
Inaba M, Fujikura R, Tsukagoshi S, Sakurai Y (1981) Restored in vitro sensitivity of adriamycin- and vincristine-resistant P388 leukaemia with reserpine. Biochem Pharmacol 30: 2191–2194
Johnson RK, Ovejera AA, Goldin A (1976) Activity of anthracyclines against and adriamycin-resistant subline of P388 leukaemia with special emphasis on cinerubin A. Cancer Treat Rep 60: 99–102
Johnson RK, Chitnis MP, Embrey WM, Gregory EB (1978) In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukaemia. Cancer Treat Rep 62: 1535–1547
Kartner N, Riordan JR, Ling V (1983a) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221: 1285–1287
Kartner N, Shales M, Riordan JR, Ling V (1983b) Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res 43: 4413–4419
Kaufman RJ, Brown PC, Schimke RT (1979)_Amplified dihydrofolate reductase genes in unstably methotrexate-resistant cells are associated with double minute chromosomes. Proc Natl Acad Sci USA 76: 5669–5673
Kaye SB, Boden JA (1980) Cross-resistance between actinomycin-D, adriamycin and vincristine in a murine solid tumour in vivo. Biochem Pharmacol 29: 1081–1084
Kennedy KA, Sigfried JM, Sartorelli AC, Tritton TR (1983) Effects of anthracyclines on oxygenated and hypoxic tumor cells. Cancer Res 43: 54–59
Kessel D (1979) Enhanced glycosylation induced by adriamycin. Mol Pharmacol 16: 306–312
Kessel D, Botterill V, Wodinsky I (1968) Uptake and retention of daunomycin by mouse leukaemic cells as factors in drug response. Cancer Res 28: 938–941
Ling V (1982) Genetic basis of drug resistance in mammalian cells. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasis, vol 1. CRC Press, Boca Raton, pp 1–19
Markland SL, Westman NG, Lundgren E, Roos G (1982) Copper-and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase and glutathione peroxidase in normal and neoplastic human cells and normal human tissues. Cancer Res 42: 1955–1959
Merry S, Freshney RI, Kaye SB (1983) Studies on the drug sensitivity of human glioma cell lines in culture. Br J Cancer 48: 118
Merry S, Kaye SB, Freshney RI (1984) Drug sensitivity of human glioma cells — the effects of verapamil. Br J Cancer (in press)
Mungikar A, Chitnis M, Gothoskar B (1981) Mixed-function oxidase enzymes in adriamycin-sensitive and resistant sublines of P388 leukaemia. Chem Biol Interact 38: 119–124
Nishimura T, Muto K, Tanaka N (1978) Drug sensitivity of an adriamycin-resistant mutant subline of mouse lymphoblastoma L5178Y cells. J Antibiot (Tokyo) 31: 493–495
Peterson RHF, Meyers MB, Spengler BA, Biedler J (1983) Alteration of plasma membrane glycopeptides and gangliosides of Chinese hamster cells accompanying development of resistance to daunomycin and vincristine. Cancer Res 43: 222–228
Ramu A, Glaubiger D, Magrath IT, Joshie A (1983a) Plasma membrane lipid structural order in doxorubicin-sensitive and-resistant P388 cells. Cancer Res 43: 5533–5537
Ramu A, Shan T, Glaubiger D (1983b) Enhancement of doxorubicin and vinblastine sensitivity in anthracycline-resistant P388 cells. Cancer Treat Rep 67: 895–899
Riehm H, Biedler JL (1971) Cellular resistance to daunomycin in Chinese hamster cells in vitro. Cancer Res 31: 409–412
Robert J, Illiadis A, Hoerni B, Cano J-P, Durand M, Lagarde C (1982) Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response, Eur J Cancer Clin Oncol 18: 739–745
Sato S, Iwaizumi M, Handa K, Tamura Y (1977) Electron spin resonance study on the mode of generation of free radicals of daunomycin, adriamycin and carbaquone in NAD(P)H-microsome system. Gan 68: 603–608
Schabel FM Jr, Skipper HE, Trader MW, Laster WR, Griswold DP Jr, Corbett TH (1983) Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67: 905–922
Shoemaker RH, Curt GA, Carney DN (1983) Evidence for multidrug-resistant cells in human tumor cell populations. Cancer Treat Rep 67: 883–888
Siegfried JA, Kennedy KA, Sasrtorelli AC, Tritton TR (1983) Role of membranes in the mechanisms of action of the antineoplastic agent adriamycin. J Biol Chem 258: 339–343
Skovsgaard T (1978) Mechanisms of resistance to daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukaemia. Biochem Pharmacol 27: 2123–2130
Skovsgaard T (1980) Circumvention of resistance to daunorubicin by N-acetyl daunorubicin in Ehrlich ascites tumor. Cancer Res 40: 1077–1081
Skovsgaard T, Friche E (1983) Circumvention of resistance to daunorubicin. In: Hansen HH (ed) Anthracyclines and cancer therapy. Excerpta Medica, Amsterdam, pp 39–48
Smith E, Stratford IJ, Adams GE (1980) Cytotoxicity of adriamycin on aerobic and hypoxic Chinese hamster V79 cells in vitro. J Cancer 42: 568–673
Smith HS, Hackett AJ, Lan S, Stampfer MR (1981) Use of an efficient method for culturing human mammary epithelial cells to study adriamycin sensitivity. Cancer Chemother Pharmacol 6: 237–240
Sutherland RM, Eddy HA, Bareham B, Reich K, Vanantwerp D (1979) Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys 5: 1225–1230
Tokes ZA, Rogers KE, Rembaum A (1982) Synthesis of adriamycin-coupled polyglutaraldehyde microspheres and evaluation of their cytostatic activity. Proc Natl Acad Sci USA 79: 2026–2030
Trent JM, Buick RN, Olson S, Horns RC Jr, Schimke RT (1984) Cytological evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma. J Clin Oncol 2: 8–15
Tritton TR, Yee G (1982) The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 217: 248–250
Tsuruo T, Ida H, Tsukagoshi S, Sakurai Y (1982) Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730–4733
Tsuruo T Iida H, Tsukagoshi S, Sakura Y (1983a) Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 43: 2267–2272
Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y (1983b) Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 43: 2905–2910
Wheeler C, Rader R, Kessel D (1982) Membrane alterations associated with progressive adriamycin resistance. Biochem Pharmacol 31: 2691–2693
Young RC, Ozols RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305: 139–153
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kaye, S., Merry, S. Tumour cell resistance to anthracyclines — A review. Cancer Chemother. Pharmacol. 14, 96–103 (1985). https://doi.org/10.1007/BF00434344
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00434344